Volume 14, Number 1—January 2008
Research
Short- and Long-term Effects of Bacterial Gastrointestinal Infections
Anders Ternhag*
, Anna Törner†, Åke Svensson†‡, Karl Ekdahl*§, and Johan Giesecke*§
, Anna Törner†, Åke Svensson†‡, Karl Ekdahl*§, and Johan Giesecke*§
Table 3
Complications associated with gastroenteritis, 3 months postinfection, among 101,855 patients with bacterial gastrointestinal infection, Sweden, 1997−2004*
| Disease | Infecting organism | Obs | Exp | SIR | 95% CI |
|---|---|---|---|---|---|
| Respiratory system | |||||
| Bacterial pneumonia, pneumonitis due to food and vomit | Nontyphoid Salmonella spp. | 24 | 13.5 | 1.8 | 1.1–2.6 |
| Campylobacter spp. | 17 | 21.4 | 0.8 | 0.5–1.3 | |
| EHEC | 1 | 0.3 | 3.1 | 0.1–17.2 | |
| Shigella spp. | 1 | 1.1 | 0.9 | 0.02–5.2 | |
| Yersinia spp. |
4 |
2.3 |
1.8 |
0.5–4.5 |
|
| Blood | |||||
| Hemolytic-uremic syndrome | Nontyphoid Salmonella spp. | 1 | <0.05 | 55.5 | 1.4–309.1 |
| Campylobacter spp. | 2 | <0.05 | 81.0 | 9.8–292.7 | |
| EHEC |
13 |
<0.05 |
18,333.4 |
9,761.8–31,350.6 |
|
| Circulatory system | |||||
| Aortic aneurysm | Nontyphoid Salmonella spp. | 10 | 1.6 | 6.4 | 3.1–11.8 |
| Campylobacter spp. | 5 | 2.4 | 2.06 | 0.7–4.8 | |
| Yersinia spp. | 1 | 0.2 | 5.2 | 0.1–28.9 | |
| Endocarditis |
Nontyphoid Salmonella spp. |
2 |
0.4 |
5.7 |
0.7–20.5 |
| Digestive system | |||||
| Peritonitis | Nontyphoid Salmonella spp. | 1 | 0.6 | 1.9 | 0.05–10.1 |
| Campylobacter spp. | 2 | 0.9 | 2.3 | 0.4–8.4 | |
| Perforation of intestine (nontraumatic) | Nontyphoid Salmonella spp. | 1 | 0.1 | 9.7 | 0.3–54.0 |
| Campylobacter spp. | 2 | 0.2 | 12.39 | 1.5–44.7 | |
| EHEC | 1 | <0.05 | 655.3 | 16.6–3,651.0 | |
| Idiopathic acute pancreatitis | Nontyphoid Salmonella spp. | 6 | 2.6 | 2.3 | 0.9–5.1 |
| Campylobacter spp. | 7 | 4.1 | 1.7 | 0.68–3.5 | |
| Hepatic failure |
Nontyphoid Salmonella spp. |
1 |
0.3 |
4.0 |
0.1–22.2 |
| Infectious diseases | |||||
| Septicemia | Nontyphoid Salmonella spp. | 10 | 2.6 | 3.9 | 1.8–7.1 |
| Campylobacter spp. | 14 | 4.1 | 3.4 | 1.9–5.7 | |
| Shigella spp. |
1 |
0.2 |
5.1 |
0.1–28.2 |
|
| Nervous system | |||||
| Guillain-Barré syndrome |
Campylobacter spp. |
13 |
0.2 |
66.6 |
35.5–114.0 |
| Musculoskeletal system | |||||
| Pyogenic arthritis | Nontyphoid Salmonella spp. | 4 | 0.8 | 5.2 | 1.4–13.4 |
| Yersinia spp. | 1 | 0.1 | 10.1 | 0.3–56.2 | |
| Osteomyelitis | Nontyphoid Salmonella spp. | 3 | 0.6 | 5.4 | 1.1–15.7 |
*Obs, observed number of cases; Exp, expected number of cases; SIR, standardized incidence ratio; CI, confidence interval; EHEC, enterohemorrhagic Escherichia coli.
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.